Journal
PANCREAS
Volume 43, Issue 7, Pages 1003-1008Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPA.0000000000000153
Keywords
pancreatic neuroendocrine tumors; new WHO grading; TNM staging; surgery; prognosis
Categories
Ask authors/readers for more resources
Objective: The objective of this study was to evaluate the clinical consistency of the new World Health Organization 2010 grading and the European Neuroendocrine Tumor Society 2006 TNM staging systems on the surgical outcome for patients with pancreatic neuroendocrine tumors (p-NETs). Moreover, we will discuss their prognostic value. Methods: The medical records of 110 consecutive patients with p-NETs who were surgically treated in our center from January 2002 to December 2012 were reviewed. Results: Sixty-five patients were diagnosed as having neuroendocrine tumor G1, 27 patients had neuroendocrine tumor G2, 14 patients had neuroendocrine carcinoma G3, and 4 patients had mixed adenoneuroendocrine carcinoma; the survival rates at 5 years were 82.6%, 52.7%, 25.7%, and 0%, respectively (P < 0.001). The TNM stage was I in 48 patients, II in 39 patients, III in 11 patients, and IV in 12 patients; the 5-year survival rates were 83.1%, 72.1%, 0%, and 0%, respectively (P < 0.001). The patients who underwent R0 resection gained a statistically longer survival time than those who did not (P < 0.001). Conclusions: Both classifications accurately reflect the clinical outcome of p-NETs. Surgical margin, the World Health Organization 2010 grading, and the TNM staging systems may all be meaningful prognostic factors impacting the long-term survival of patients with p-NETs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available